News

DPHARMA

1.280

-0.030 (-2.3%)
Language:

CIMB Securities dismisses Duopharma's insulin market share loss to Pharmaniaga as 'neutral' event

CIMB Securities said the reshuffling of the government's human insulin contract was a "neutral" development for Duopharma Biotech Bhd (KL:DPHARMA), despite the company losing its lead supplier status to Pharmaniaga Bhd (KL:PHARMA).
TheEdge03 Apr, 2026 17:34pm - 2 days

传发马获政府医院2.8亿合约

（吉隆坡1日讯）消息指出，发马（PHARMA,7081,主板医疗保健组）已获得首份向政府医院供应人胰岛素的合约，价值2亿8167万令吉。股价涨6.1%受此利好消息激励，该公司股价应声走高，一度涨至26.5仙，闭市报26仙，全日共涨1.5仙或6.1%，成交量共3767万2100股。知情人士向《The Edge》透露，该合约为期3年，预计发马将在蒲种工厂自行生产该产品，这使其成为我国首家生产人胰岛素的本土企业。政府采购网站的查询结果也证实这一点，显示该采购合约于3月10日授予发马子公司Pha...
Sinchew01 Apr, 2026 20:28pm - 3 days

消息：赢得2.82亿政府合约 发马将成为首家本地人胰岛素生产商

（吉隆坡1日讯）据知情人士向The Edge透露，发马（Pharmaniaga Bhd）（KL:PHARMA）已获得首份向政府医院供应人胰岛素的合约，价值2亿8167万令吉。
TheEdge01 Apr, 2026 09:34am - 4 days

Pharmaniaga set to be first local human insulin producer with RM282 mil govt contract win — sources

Pharmaniaga Bhd (KL:PHARMA) has secured its first contract to supply human insulin to government hospitals, worth RM281.67 million, sources close to the matter told The Edge.
TheEdge01 Apr, 2026 08:30am - 4 days

Duopharma to be bolstered by stronger ringgit

Duopharma Biotech Bhd maintains the view that the impact of the Middle East conflict remains manageable for now, supported by the group's inventory buffer of three to six months' worth of active pharmaceutical ingredients (API) alongside the strengthening ringgit, analysts say.
TheStar01 Apr, 2026 00:00am - 4 days

【行家论股】联合药业 料调价缓解成本压力

联合药业在末季业绩汇报会表示，其采取的战略举措有效缓解原料成本上升的影响，进一步巩固分析师对其前景的看好预期。...
Nanyang31 Mar, 2026 17:55pm - 5 days

达证券：联合药业或将获得新胰岛素合约

（吉隆坡31日讯）达证券指出，联合药业（Duopharma Biotech Bhd）（KL:DPHARMA）可能很快会获得一份新合约，继续向政府供应人胰岛素制剂。
TheEdge31 Mar, 2026 12:10pm - 5 days

Duopharma may secure new insulin contract, TA Securities tips

Duopharma Biotech Bhd (KL:DPHARMA) could soon secure a new contract to supply human insulin formulations to the government, according to TA Securities.
TheEdge31 Mar, 2026 10:35am - 5 days

Malaysia's healthcare sector seen as defensive haven amid market volatility

KUALA LUMPUR: Malaysia’s healthcare sector continues to serve as a resilient defensive haven amid rising geopolitical tensions and persistent inflationary pressures, said RHB Research.
NST26 Mar, 2026 08:58am - 1 week

Resilient demand to power healthcare sector

Malaysia's healthcare sector is expected to remain a preferred defensive play in 2026, underpinned by resilient domestic demand, rising revenue intensity and stronger earnings visibility.
TheStar26 Mar, 2026 00:00am - 1 week

Contractors, material firms face cost pressures amid Middle East conflict, CIMB Securities flags

Malaysian contractors and building materials companies may face margin pressure from rising costs amid escalating conflict in the Middle East, CIMB Securities said.
TheEdge04 Mar, 2026 13:01pm - 1 month

Trading ideas: MMHE, TM, Gadang, Duopharma, MNRB, Cepatwawasan

KUALA LUMPUR: Here is a recap of the announcements that made headlines in Corporate Malaysia.
TheStar04 Mar, 2026 08:22am - 1 month

Tabung Haji muncul pemegang saham besar Duopharma Biotech

KUALA LUMPUR: Lembaga Tabung Haji muncul sebagai pemegang saham besar dalam Duopharma Biotech Bhd susulan pemerolehan terbaharu saham dalam syarikat pengeluar ubat itu.
BeritaHarian03 Mar, 2026 22:47pm - 1 month

Telekom Malaysia, BHIC, MNRB, Rivertree, Gadang, Northern Solar, MHB, Duopharma & Cepatwawasan

Here is a brief recap of some business news and corporate announcements that made the headlines on Tuesday.
TheEdge03 Mar, 2026 22:39pm - 1 month

Tabung Haji emerges as substantial shareholder in Duopharma

Lembaga Tabung Haji has emerged as a substantial shareholder of Duopharma Biotech Bhd (KL:DPHARMA), following its latest acquisition of shares in the drugmaker.
TheEdge03 Mar, 2026 19:29pm - 1 month

吴继宗|联合药业获政府合约支撑

联合药业（DPHARMA,7148,主板医疗保健组）政府订单持续扩张，机构资金回流下的中期结构正在形成。联合药业集团在最新公布的2025年第四季业绩中，营业额达到2亿2468万6000令吉，较上一季度微升0.99%，显示整体业务维持稳定增长。净利方面录得1904万8000令吉，虽然较上一季下滑15.61%，但年对年仍取得26%的增长，反映集团整体盈利能力仍处于改善趋势。与此同时，公司持续受惠于大马医疗政策扩张，政府在2026年财政预算案中提高卫生部拨款，加上第13大马计划继续强化医疗体系及本...
Sinchew02 Mar, 2026 08:10am - 1 month

Duopharma FY25 core earnings exceed expectations

KUALA LUMPUR: Duopharma Biotech Bhd’s results for the financial year ended Dec 31, 2025 (FY25) beat estimates on the back of a strong fourth quarter (Q4), driven by robust private market demand and sustained margins.
NST01 Mar, 2026 14:11pm - 1 month

Trading ideas: Maybank, Affin, MBSB, TNB, YTL, Genting, Press Metal, Axiata, IJM, DRB-Hicom, AirAsia X, Zetrix, Duopharma, KPJ, Inari, 7-Eleven, Sime Darby

Trading ideas: Maybank, Affin, MBSB, TNB, YTL, Genting, Press Metal, Axiata, IJM, DRB-Hicom, AirAsia X, Zetrix, Duopharma, KPJ, Inari, 7-Eleven, Sime Darby
TheStar27 Feb, 2026 08:11am - 1 month

Maybank, Affin Bank, MBSB, YTL Corp, YTL Power, Malayan Cement, TNB, Genting, GenM, Press Metal, Axiata, IJM, DRB-Hicom, AAX, Zetrix AI, Duopharma, KPJ, Inari Amertron, 7-Eleven, Sime Darby, UEM Sunrise & Takaful Malaysia

Here is a brief recap of some business news and corporate announcements that made the headlines on Thursday.
TheEdge27 Feb, 2026 02:15am - 1 month

Duopharma to focus on enhancing operational efficiencies

PETALING JAYA: Duopharma Biotech Bhd will remain proactively focused on enhancing operational efficiencies, optimising cost management strategies, and disciplined execution of its strategic initiatives.
TheStar26 Feb, 2026 21:18pm - 1 month
Load more